'Female Viagra' Gets Thumbs Down From FDA Panel
An expert U.S. Food and Drug Administration panel at a hearing Friday did not recommended approval for a German drug company's pill aimed at premenopausal women distressed by low sexual desire.
Had the expert panel OKed the drug for this indication and had the FDA eventually approved flibanserin, the drug company would have gotten some fringe benefits too -- an estimated $2 billion in profits, equal or greater than annual sales of the three top men's sex drugs,Viagra,Levitra and Cialis.
Critics, however, argue that drug companies have essentially created a disease -- hypoactive sexual desire disorder -- for the natural ebbs and flows of a woman's sexuality to market a drug. They say the pharmaceutical industry is putting women at risk for side effects that come from taking this pill daily.
What We Do
NCRW is a network of leading university and community based research, policy, and advocacy centers with a growing global reach dedicated to advancing rights and opportunities for women and girls. We also have a Corporate Circle comprised of senior diversity professionals from leading U.S. and global member companies and a Presidents Circle of college and university leaders who share our commitment. NCRW harnesses the collective power of its network to provide knowledge, analysis, and thought leadership on issues ranging from reducing women’s poverty to building a critical mass of women’s leadership across sectors.
Print-friendly
Send to friend